Skip to main content
. 2015 Oct 17;6(41):44049–44056. doi: 10.18632/oncotarget.5833

Figure 1. Dose-exposure and serum profile of XC-302 in 21 patients with relapsed or refractory non-Hodgkin's lymphoma.

Figure 1

A. Steady-state (day 1 and day 28) XC-302 plasma exposures by XC-302 dosing regimen (N = 21). AUClast, area under the curve from time zero to the last detectable value; Cmax, maximum XC-302 concentration. Mean plasma concentration–time profiles, B. day 1 and C. day 28. SEM, standard error of the mean.